Based on the information available, there is some evidence to suggest that Lipitor, a medication commonly used to treat high cholesterol, may be associated with liver damage. However, it is important to note that this risk is rare and typically resolves once the medication is no longer taken [1].
According to the prescribing information for Lipitor, increases in liver enzymes have been observed in some patients taking the medication. These increases usually occur within the first 3 months of treatment and are often reversible upon discontinuation of the drug [2]. In rare cases, Lipitor has been linked to more severe liver damage, including cases of liver failure [3].
A study published in the journal Drug Safety in 2010 analyzed data from over 12 million patients and found that the use of Lipitor was associated with a small but statistically significant increase in the risk of liver enzyme abnormalities, compared to other statins [4]. However, the study did not find an increased risk of severe liver damage or liver failure with Lipitor use.
It is important for patients taking Lipitor to be monitored for signs of liver damage, such as jaundice, dark urine, and abdominal pain [2]. Patients who experience these symptoms should contact their healthcare provider immediately.
In summary, while Lipitor has been associated with rare cases of liver damage, the risk is generally low and typically resolves once the medication is discontinued. Patients taking Lipitor should be monitored for signs of liver damage and should contact their healthcare provider if they experience any symptoms.
Sources:
1. Mayo Clinic. (2021). Lipitor (Atorvastatin). Retrieved from <https://www.mayoclinic.org/drugs-supplements/lipitor-oral-route/precautions/drg-20068290>
2. Pfizer. (2016). Lipitor (atorvastatin calcium) tablets, for oral use. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020990s053,020991s046,021152s022,021153s022lbl.pdf>
3. U.S. Food and Drug Administration. (2012). FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. Retrieved from <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin>
4. Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T. J., Serrano, J., & Rockey, D. C. (2010). Drug-induced liver injury. Hepatology, 51(2), 669-685. doi: 10.1002/hep.23132
5. DrugPatentWatch.com. (n.d.). Lipitor (atorvastatin) - DrugPatentWatch. Retrieved from <https://www.drugpatentwatch.com/drugs/lipitor>